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Patients with the acquired immunodeficiency syndrome (AIDS) are character-
ized by a decrease in the number ofT helper cells, a defect that is linked to the
impaired immunologic competence. Vitamin A and its dietary precursor, beta-
carotene, increase absoluteThelper cell counts as well as indices ofTcell func-
tion inboth human and animal models. Todetermine ifshort-term beta-carotene
treatment affects T lymphocyte subsets in patients with AIDS, a single-blind,
non-randomized clinical trial of beta-carotene was performed in seven patients
withAIDS. Enrollment criteria included no evidence of: a) active opportunistic
infection; b) greater than 1 kilogram change in weight in the month preceding
enrollment; c) chronic diarrhea or malabsorption; and d) hepatic disease or sig-
nificant anemia. Beta-carotene was given with meals in two divided doses of60
mg/day for four weeks; this was followed by no therapy for six weeks. Samples
for total white blood cell, lymphocyte and T lymphocyte subset counts were
measured at baseline, at the end of four weeks of treatment and another six
weeks after treatment had stopped. P24 antigen, beta-2 microglobulin and liver
function tests were also measured.
All subjects tolerated the treatment well without evidence of toxicity. In
response to beta-carotene, total lymphocyte counts rose by 66 percent (.05 < p
<.10), and CD4+ cells rose slightly, but insignificantly, in the entire group. In
all three of the patients who had baseline CD4+ cells greater than 10/j1, how-
ever, the mean absolute increase in CD4+ cells in response to beta-carotene was
53 + 10 cells/gl (p < .01). Six weeks off beta-carotene treatment, the absolute
CD4+ cell count returned to pretreatment levels (p < .01). No change was
observed in CD8+ cells. P24 antigen and beta-2 microglobulin did not change
during treatment. These preliminary observations suggest that short-term treat-
ment with beta-carotene may increase CD4+ cell counts in patients with AIDS
who have greater than 10 cells/,ul.
INTRODUCTION
Interest in vitaminA andrelated compounds to modulate human diseases has expand-
ed in recent years. In children, dietary supplementation with vitamin A reduces mortality
due to measles by 60 percent [1], even without clinical signs ofdeficiency [1]. In animals,
vitamin A deficiency augments mortality due to a variety of infective organisms [2], and
conversely, dietary supplementation enhances survival [2] and lessens morbidity [3].
Although all of the mechanism(s) of vitamin A action are not known on an immunologic
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basis, vitamin A increases absolute T helper cell counts [4] as well as indices of T cell
function, such as skin graft rejection [5, 6] or mixed lymphocyte response [7].
Beta-carotene, the major dietary precursor of vitamin A, has similar effects on the
immune system. In normal humans, beta-carotene increased OKT4 positive T cells by 40
percent [8, 9] without affecting OKT8 cells. Given these properties ofvitamin A and beta-
carotene, we conducted a preliminary trial of beta-carotene in patients with the acquired
immunodeficiency syndrome (AIDS/, which is characterized by impaired immunologic
defenses in the setting of a dearth ofT helper cells. We chose beta-carotene over vitamin
A because of a lower incidence oftoxicity [10].
METHODS
Seven patients (six male/one female; mean age 34 + 3 yr) with Centers for Disease
Control and Prevention clinical criteria forAIDS were enrolled in this single-blind study
(Table 1). The AIDS defining diagnoses were: pneumocystis pneumonia (four patients),
Kaposi's sarcoma (one), candida esophagitis (two). The mean time after diagnosis of
AIDS was 67 + 20 weeks (range 26-164). Eligibility criteria included no evidence of:
opportunistic infection, > 1 kg change in weight in the month preceding enrollment,
chronic diarrhea or malabsorption, hepatic disease (defined by AST orALT > 2x normal)
or significant anemia (hemoglobin < 10g/dl).
Patients received beta-carotene (Solatene, Hoffmann-LaRoche, Inc.) 60 mg/day in
two divided doses with meals for four weeks as well as a daily multi-vitamin to supply
100 percent ofthe recommended daily allowance of zinc and vitamin E. No new medica-
tions were given to any ofthe patients during the study. Each patient continued, however,
with his/her ongoing medications, including zidovudine. The duration ofzidovudine ther-
apy was 52 + 11 weeks (range 16-94). Prior to treatment, all subjects had single baseline
measurements of: complete blood count and differential; serum electrolytes and liver
function tests; and total lymphocytes and CD4+ and CD8+ subsets. Repeat samples were
drawn at approximately the same time of day at the end of four weeks of beta-carotene
and then at week 10 (six weeks later offtherapy). Conventional and acid dissociated p24
antigen and beta-2 microglobulin were also sampled in all subjects at the baseline and
Table 1. Baseline characteristics ofstudy patients.
Duration AZT
Age AIDS ofAIDS Therapy CD4+ Weight
Patient (yrs) Gender diagnosis (wks) (wks) cells/gl (kg)
1 45 Male Candida 56 64 144 83
esophagitis
2 38 Male AIDS 88 92 99 60
dementia
3 37 Male PCP 20 20 7 80
4 24 Male PCP 91 94 5 71
5 27 Male PCP 164 40 100 76
6 34 Male KS 26 28 5 57
7 33 Female Candida 26 16 9 61
esophagitis
Mean+ 33+3 67+20 52+ 11 60+21 70+3
SEM
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Figure 1. Effect ofbeta-carotene on T cell subsets. Total CD4+ and CD8+ cell counts before (0),
at the end offour weeks (4) and six weeks offtreatment (10) in seven patients with AIDS.
week-four time points and at week 10 for subjects 1 to 3. The T cell measurements were
done using flow cytometry. All subjects gave informed consent prior to participation,
which was approved by the Human Investigation Committee oftheYale University School
of Medicine. An ANOVA for repeated measures with post-hoc testing (Duncan's) was
used for statistical comparisons ofdata (True Epistat, Richardson, Texas). Data are report-
ed as mean + SEM.
RESULTS
All patients tolerated the treatment well; the only side-effect was carotenodermia,
which faded after discontinuation of the beta-carotene. No changes in weight or hepatic
function were observed. For the entire group, total white blood cell counts did not change
but total lymphocyte counts increased from 0.56 + 0.09 to 0.93 + 0.24 (x 103/Jl; .05 < p
<.10) between baseline and at the end ofbeta-carotene treatment. Figure 1 summarizes T
cell subset changes during the study. For the entire group ofpatients, CD4+ cells tended
to increase in response to beta-carotene, but this change was statistically insignificant (p
< .14). Three of these patients had baseline CD4+ cells greater than 10/,I. Their CD4+
counts demonstrated an average increase of53 + 10 cells/,l (or 43 + 9 percent over base-
line; p < .01 by ANOVA, p < .01 baseline vs. four weeks). Total white blood cell counts
increased 23 percent in these three patients, from 3.0 + 0.3 to 3.7 + 0.03 (x 103/,l) due to
an increase in total lymphocytes (0.82 + 0.01 to 1.47 + 0.29, x 103/4l). Six weeks after
discontinuing beta-carotene, CD4+ cells returned to baseline values in these three patients
(p < .01, 4 vs. 10 weeks). It is noteworthy that patient two also had T cell subsets mea-
sured after two weeks of beta-carotene. His CD4+ cells had shown an increase to 134/pl
from 94/,l at baseline. At four weeks oftreatment, his CD4+ cell count was 164/41.
As with CD4+ cells, CD8+ cells did not change in the group as a whole. In all three
subjects with CD4+ cells greater than 10/,u, CD8+ cells increased from 479 + 49 to 881
+ 211/gJ. Due to a large change in single subject, this was not statistically significant. No
change was observed in individual CD4+/CD8+ ratios. Acid dissociated p24 antigen was
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detectable in only three of seven patients and did not change in response to beta-carotene.
Similarly, beta-2 microglobulin levels were unaffected by beta-carotene (data not shown).
DISCUSSION
The data from this pilot study suggest that beta-carotene increases the CD4+ cell pop-
ulation inAIDS patients who have greaterthan 10cells/pl. The response ofthe small num-
ber ofpatients in the present study is consistent with that observed in normal adults and
related effects of vitamin A in animals, i.e., biologically significant increases in CD4+
cells [4, 8, 9]. Although this study focused on patients with AIDS [11], three other trials
of beta-carotene in HIV-infected patients have recently been reported. Coodley et al. [12]
treated HIV-seropositive patients with beta-carotene (180 mg/day in three divided doses)
for four weeks. In comparison to placebo, significant fractional increases were observed
in their patients, whose helper cell counts ranged from less than 200 to greater than
500/,l. Those patients with helper cell counts less than 200/pl demonstrated the greatest
change in helper cells (+30 percent with beta-carotene compared with -36 percent on
placebo). Garewal et al. [13] treated 11 HIV-positive patients with a single, daily dose of
beta-carotene (60 mg) for four months. These investigators observed an approximate 50
percent increase in NK cells but without changes in CD4+ cells in the entire group. No
data were provided on responses to beta-carotene when analyzed as a function ofbaseline
measurements. Although both Coodley et al. [12] and Garewal et al. [13] studied HIV-
seropositive patients, it is not known ifany ofthe patients had clinical manifestations that
characterize AIDS. Bianchi-Santamaria et al. [14] recently treated nine AIDS-related
complex (ARC) patients with beta-carotene for six to 21 months. In response to treatment,
CD4+ cell counts rose by 11.5 percent, a change that was statistically insignificant.
Clinically, however, symptomatic asthenia, feverishness, sweating and diarrhea resolved.
None ofthese patients progressed toAIDS during the six to 21-month observation period.
In spite of the positive response observed in the present study, the CD4+ counts at
four weeks were still subnormal. It has been demonstrated, however, that the risks for
acquiring different opportunistic infections are related to the absolute helper cell count
within the subnormal range [15]. Increases in helper T cell number, therefore, may alter
these risks. The lack of response in the more significantly CD4+ depleted group may be
due to end-stage immunologic dysfunction or a time-dependent factor, since the short
treatment period may not have been long enough to elicit an increase.
Recent observations have suggested that vitamin A deficiency is strongly associated
with an increased risk ofdeath in patients withAIDS [16]. In this study ofa cohort ofdrug
abusers in Baltimore, along with depressed CD4 counts, serum retinol levels below 1.05
jmollL predicted a four-fold increased risk of death. Moreover, serum retinol [16] or
carotene [17] levels correlate with CD4 counts. In HIV positive mothers and their off-
spring, maternal vitaminA deficiency was associated with an increased risk ofHIV trans-
mission to the neonate [18]. Thus, available indicators suggest that vitamin A deficiency
is associated with an increased risk of death. It is recognized that although these studies
provide strong associations between vitaminA deficiency and adverse outcome in patients
with AIDS, many other variables are also affected in these patients, such that vitamin A
deficiency may be aharbinger but not a cause ofdeath. For the present study, it is empha-
sized that firm, statistically sound conclusions about the efficacy of beta-carotene cannot
be based upon the responses of the three subjects with CD4 counts greater than l0/uL.
Rather, these results need to be considered preliminary. However, when considered in
combination with other cited work, the present study forms the spark to encourage larger
and longer trials of beta-carotene in this patient population, specifically a double-blind,
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placebo and diet-controlled study with an adequate number ofpatients treated for at least
three months time.
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